Nephrologisches Zentrum Villingen-Schwenningen

Villingen-Schwenningen 78052

3 studies enrolling now · 8 studies all time

What they study most

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease, Chronic Kidney Disease (CKD), Coronary Heart Disease (CHD), End Stage Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS), IgA Nephropathy, Immunoglobulin A Nephropathy, Kidney Disease, Chronic, Primary IgA Nephropathy

Studies at this site

• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression — Recruiting now
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — Running, not enrolling
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• Atrasentan in Patients With IgA Nephropathy — Running, not enrolling
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) — Completed
• A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) — Stopped early